DOCSLIB.ORG

Human Annexin A1 Elisa

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Human Annexin A1 Elisa HUMAN ANNEXIN A1 ELISA Product Data Sheet Cat. No.: RD191371200R For Research Use Only Page 1 of 24 ENG.001.A CONTENTS 1. INTENDED USE 3 2. STORAGE, EXPIRATION 3 3. INTRODUCTION 4 4. TEST PRINCIPLE 6 5. PRECAUTIONS 6 6. TECHNICAL HINTS 7 7. REAGENT SUPPLIED 7 8. MATERIAL REQUIRED BUT NOT SUPPLIED 8 9. PREPARATION OF REAGENTS 8 10. PREPARATION OF SAMPLES 10 11. ASSAY PROCEDURE 11 12. CALCULATIONS 13 13. PERFORMANCE CHARACTERISTICS 14 14. DEFINITION OF THE STANDARD 17 15. PRELIMINARY POPULATION DATA 17 16. METHOD COMPARISON 18 17. TROUBLESHOOTING AND FAQS 19 18. REFERENCES 20 19. EXPLANATION OF SYMBOLS 21 This kit is manufactured by: BioVendor – Laboratorní medicína a.s. Use only the current version of Product Data Sheet enclosed with the kit! Page 2 of 24 ENG.001.A 1. INTENDED USE The RD191371200R Human Annexin A1 ELISA is a sandwich enzyme immunoassay for the quantitative measurement of human annexin A1. Features It is intended for research use only The total assay time is less than 3.5 hours The kit measures annexin A1 in human serum, plasma (EDTA, citrate, heparin), urine and saliva samples Assay format is 96 wells Standard is recombinant protein based Components of the kit are provided ready to use, concentrated or lyophilized 2. STORAGE, EXPIRATION Store the complete kit at 2 – 8 °C. Under these conditions, the kit is stable until the expiration date (see label on the box). For stability of opened reagents see Chapter 9. Page 3 of 24 ENG.001.A 3. INTRODUCTION The annexin superfamily is composed of 12 members in humans [1], characterized by the unique Ca2+-binding-site architecture, which enables them to peripherally attach to negatively charged membrane surfaces [2,3]. Annexin A1 (AnxA1), also known as annexin I or lipocortin I, was characterized as a glucocorticoid-regulated anti-inflammatory protein [4,5]. This 37-kDa protein is comprised of a homologous core region of 310 amino acid residues, representing almost 90% of the structure, attached to a unique N-terminal region [3]. AnxA1 is a Ca2+-regulated phospholipid-binding protein [6]. To mediate membrane binding, Ca2+ ions can induce a conformational change that leads to the exposure of the bioactive N-terminal domain [3,7,8]. The different functions of AnxA1 lie within the unique N-terminus [9]. AnxA1 is expressed in several tissues and involved in different cell processes including cell survival, proliferation, apoptosis, differentiation and migration [10]. AnxA1 can be nuclear, cytoplasmic and/or membrane-associated [2,11,12]. Depending on the human tissue/cell line, AnxA1 can be cleaved at different positions by different proteases [6]. The membrane- associated AnxA1 can be proteolytically cleaved to become accessible to its cognate partners, the formyl-peptide receptors (FPRs) [6]. The AnxA1/FPR complex has been found to be involved in inflammation [5], neuroendocrine system regulation [13], skeletal muscle differentiation [14] and cancer progression [15]. To date, FPRs are the only known receptors of externalized AnxA1 [6]. As these receptors can be activated or silenced by a variety of synthetic ligands, they represent an attractive family of pharmacological targets [16]. AnxA1 and inflammation: AnxA1 is able to counterregulate inflammatory events [4]. AnxA1 and its mimetic peptides inhibit neutrophil tissue accumulation by reducing leukocyte infiltration and activating neutrophil apoptosis [4]. Some evidence has suggested the ability of AnxA1 to induce macrophage reprogramming towards a resolving phenotype, resulting in reduced production of proinflammatory cytokines and increased release of immunosuppressive and proresolving molecules [4]. Thus, AnxA1 could be a promising tool for development of new therapeutic strategies for treating inflammatory diseases [4]. AnxA1 and cancer: Deregulation of AnxA1 often correlates with cancer, and its role in tumour initiation, proliferation and metastases has been established [15,17]. AnxA1 could be a tumorigenic mediator between cancer cells and their microenvironment [6]. Efficient inhibitors of AnxA1 could potentiate cell response to chemotherapy [6]. The overexpression of AnxA1 in the cytoplasm of tumour cells has been observed in several cancers [18]. AnxA1 is specifically expressed in tumour vasculature (at least in breast, kidney, liver, lung, brain and prostate cancers) and could be a promising target for human tumour imaging, drug delivery and internal radiotherapy [6]. In some cancers, AnxA1 is found at the cell surface, where it stimulates FPRs to trigger oncogenic pathways [6]. Page 4 of 24 ENG.001.A Areas of investigation: Immune Response, Infection and Inflammation Autoimmunity Oncology Apoptosis Page 5 of 24 ENG.001.A 4. TEST PRINCIPLE In the BioVendor Human Annexin A1 ELISA, standards and samples are incubated in microplate wells pre-coated with polyclonal anti-human annexin A1 antibody. After 60 minutes incubation followed by washing, biotin-labelled polyclonal anti-human annexin A1 antibody is added and incubated with the captured annexin A1 for 60 minutes. After another washing, streptavidin-HRP conjugate is added. After 30 minutes incubation and the last washing step, the remaining conjugate is allowed to react with the substrate solution (TMB). The reaction is stopped by addition of acidic solution and absorbance of the resulting yellow product is measured. The absorbance is proportional to the concentration of annexin A1. A standard curve is constructed by plotting absorbance values against concentrations of standards and concentrations of unknown samples are determined using this standard curve. 5. PRECAUTIONS For professional use only Notice: Wear gloves, face mask (or another mouth covering), hair cover and laboratory coat when handling ELISA components and during ELISA assay. Skin flakes and saliva can contain annexin A1 protein and contamination in any ELISA step could cause false positive results Do not drink, eat or smoke in the areas where immunodiagnostic materials are being handled This kit contains components of human or animal origin. These materials should be handled as potentially infectious Avoid contact with the acidic Stop Solution and Substrate Solution, which contains hydrogen peroxide and tetramethylbenzidine (TMB). Wear gloves and eye and clothing protection when handling these reagents. Stop and/or Substrate Solutions may cause skin/eyes irritation. In case of contact with the Stop Solution and the Substrate Solution wash skin/eyes thoroughly with water and seek medical attention, when necessary The materials must not be pipetted by mouth Page 6 of 24 ENG.001.A 6. TECHNICAL HINTS Reagents with different lot numbers should not be mixed Use thoroughly clean glassware Use deionized (distilled) water, stored in clean containers Avoid any contamination among samples and reagents. For this purpose, disposable tips should be used for each sample and reagent Substrate Solution should remain colourless until added to the plate. Keep Substrate Solution protected from light Stop Solution should remain colourless until added to the plate. The colour developed in the wells will turn from blue to yellow immediately after the addition of the Stop Solution. Wells that are green in colour indicate that the Stop Solution has not been mixed thoroughly with the Substrate Solution Dispose consumable materials and unused contents in accordance with applicable national regulatory requirements 7. REAGENT SUPPLIED Kit Components State Quantity Antibody Coated Microtiter Strips ready to use 96 wells Biotin Labelled Antibody Conc. (100x) concentrated 0.13 ml Streptavidin-HRP Conjugate ready to use 13 ml Master Standard lyophilized 2 vials Dilution Buffer ready to use 50 ml Wash Solution Conc. (10x) concentrated 100 ml Substrate Solution ready to use 13 ml Stop Solution ready to use 13 ml Product Data Sheet + Certificate of Analysis - 1 pc Page 7 of 24 ENG.001.A 8. MATERIAL REQUIRED BUT NOT SUPPLIED Deionized (distilled) water Test tubes for diluting samples Glassware (graduated cylinder and bottle) for Wash Solution (Dilution Buffer) Precise pipettes to deliver 5 – 1000 l with disposable tips Multichannel pipette to deliver 100 l with disposable tips Plate cover Absorbent material (e.g. paper towels) for blotting the microtiter plate after washing Vortex mixer Incubator adjustable to 37 °C Microplate washer (optional). [Manual washing is possible but not preferred] Microplate reader with 450 10 nm filter, preferably with reference wavelength 630 nm (alternatively another one from the interval 550 – 650 nm) Software package facilitating data generation and analysis (optional) 9. PREPARATION OF REAGENTS All reagents need to be brought to room temperature prior to use Always prepare only the appropriate quantity of reagents for your test Do not use components after the expiration date marked on their label Assay reagents supplied ready to use: Antibody Coated Microtiter Strips Stability and storage: Return the unused strips to the provided aluminium zip-sealed bag with desiccant and seal carefully. Remaining Microtiter Strips are stable 3 months stored at 2 - 8 °C and protected from the moisture. Streptavidin-HRP Conjugate Dilution Buffer Substrate Solution Stop Solution Stability and storage: Opened reagents are stable 3 months when stored at 2 - 8 °C. Page 8 of 24 ENG.001.A Assay reagents supplied concentrated or lyophilized: Human Annexin A1 Master Standard Refer to the Certificate of Analysis for current volume of Dilution Buffer needed for reconstitution of standard!!! Reconstitute the lyophilized Master Standard with Dilution Buffer just prior to the assay. Let it dissolve at least 15 minutes with occasional gentle shaking (not to foam). Vortex is recommended. The resulting concentration of human annexin A1 in the stock solution is 3.2 ng/ml. Prepare set of standards using Dilution Buffer as follows: Volume of Standard Dilution Buffer Concentration Stock - 3.2 ng/ml 250 l of stock 250 l 1.6 ng/ml 250 l of 1.6 ng/ml 250 l 0.8 ng/ml 250 l of 0.8 ng/ml 250 l 0.4 ng/ml 250 l of 0.4 ng/ml 250 l 0.2 ng/ml 250 l of 0.2 ng/ml 250 l 0.1 ng/ml Prepared Standards are ready to use, do not dilute them.
Load more

Recommended publications
  • Annexin A2 Flop-Out Mediates the Non-Vesicular Release of Damps/Alarmins from C6 Glioma Cells Induced by Serum-Free Conditions
    cells Article Annexin A2 Flop-Out Mediates the Non-Vesicular Release of DAMPs/Alarmins from C6 Glioma Cells Induced by Serum-Free Conditions Hayato Matsunaga 1,2,† , Sebok Kumar Halder 1,3,† and Hiroshi Ueda 1,4,* 1 Pharmacology and Therapeutic Innovation, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8521, Japan; [email protected] (H.M.); [email protected] (S.K.H.) 2 Department of Medical Pharmacology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8523, Japan 3 San Diego Biomedical Research Institute, San Diego, CA 92121, USA 4 Department of Molecular Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto 606-8501, Japan * Correspondence: [email protected]; Tel.: +81-75-753-4536 † These authors contributed equally to this work. Abstract: Prothymosin alpha (ProTα) and S100A13 are released from C6 glioma cells under serum- free conditions via membrane tethering mediated by Ca2+-dependent interactions between S100A13 and p40 synaptotagmin-1 (Syt-1), which is further associated with plasma membrane syntaxin-1 (Stx-1). The present study revealed that S100A13 interacted with annexin A2 (ANXA2) and this interaction was enhanced by Ca2+ and p40 Syt-1. Amlexanox (Amx) inhibited the association between S100A13 and ANXA2 in C6 glioma cells cultured under serum-free conditions in the in situ proximity ligation assay. In the absence of Amx, however, the serum-free stress results in a flop-out of ANXA2 Citation: Matsunaga, H.; Halder, through the membrane, without the extracellular release. The intracellular delivery of anti-ANXA2 S.K.; Ueda, H. Annexin A2 Flop-Out antibody blocked the serum-free stress-induced cellular loss of ProTα, S100A13, and Syt-1.
    [Show full text]
  • The Impact of Endogenous Annexin A1 on Glucocorticoid Control of Infl Ammatory Arthritis
    Basic and translational research Ann Rheum Dis: first published as 10.1136/annrheumdis-2011-201180 on 5 May 2012. Downloaded from EXTENDED REPORT The impact of endogenous annexin A1 on glucocorticoid control of inß ammatory arthritis Hetal B Patel,1 Kristin N Kornerup,1 AndreÕ LF Sampaio,1 Fulvio DÕAcquisto,1 Michael P Seed,1 Ana Paula Girol,2 Mohini Gray,3 Costantino Pitzalis,1 Sonia M Oliani,2 Mauro Perretti1 ▶ Additional (Þ gures and tables) ABSTRACT Annexin A1 (AnxA1) is an effector of resolution.4 are published online only. To view Objectives To establish the role and effect of Highly expressed in immune cells (eg, polymorpho- these Þ les please visit the journal nuclear cells and macrophages), this protein is exter- online (http://ard.bmj.com/ glucocorticoids and the endogenous annexin A1 (AnxA1) content/early/recent). pathway in inß ammatory arthritis. nalised to exert paracrine and juxtacrine effects, the vast majority of which are mediated by the formyl- 1William Harvey Research Methods Ankle joint mRNA and protein expression Institute, Barts and The London of AnxA1 and its receptors were analysed in peptide receptor type 2 (FPR2/ALX ([Lipoxin A4 School of Medicine, London UK naive and arthritic mice by real-time PCR and receptor]) or FPR2, in rodents).5 Intriguingly, FPR2/ 2Department of Biology; 6 immunohistochemistry. Inß ammatory arthritis was ALX is also the lipoxin A4 receptor indicating the Instituto de Bioci•ncias, Letras +/+ existence of important – yet not fully appreci- e Ci•ncias Exatas (IBILCE), S‹o induced with the K/BxN arthritogenic serum in AnxA1 −/− ated – networks in resolution.7 Paulo State University, S‹o JosŽ and AnxA1 mice; in some experiments, animals Another receptor do Rio Preto, Brazil were treated with dexamethasone (Dex) or with human is also advocated to mediate the effects of AnxA1, 3Medical Research Council recombinant AnxA1 or a protease-resistant mutant the formyl-peptide receptor type 1 or FPR1 (FPR1 Centre for Inß ammation, (termed SuperAnxA1).
    [Show full text]
  • Annexin A1 Expression Is Associated with Epithelial–Mesenchymal Transition (EMT), Cell Proliferation, Prognosis, and Drug Response in Pancreatic Cancer
    cells Article Annexin A1 Expression Is Associated with Epithelial–Mesenchymal Transition (EMT), Cell Proliferation, Prognosis, and Drug Response in Pancreatic Cancer Masanori Oshi 1,2 , Yoshihisa Tokumaru 1,3 , Swagoto Mukhopadhyay 1, Li Yan 4, Ryusei Matsuyama 2, Itaru Endo 2 and Kazuaki Takabe 1,2,5,6,7,8,* 1 Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA; [email protected] (M.O.); [email protected] (Y.T.); [email protected] (S.M.) 2 Department of Gastroenterological Surgery, Yokohama City University School of Medicine, Yokohama, Kanagawa 236-0004, Japan; [email protected] (R.M.); [email protected] (I.E.) 3 Department of Surgical Oncology, Graduate School of Medicine, Gifu University, 1-1 Yanagido, Gifu 501-1194, Japan 4 Department of Biostatistics & Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA; [email protected] 5 Department of Gastrointestinal Tract Surgery, Fukushima Medical University School of Medicine, Fukushima 960-1295, Japan 6 Department of Surgery, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo the State University of New York, Buffalo, NY 14263, USA 7 Department of Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8510, Japan Citation: Oshi, M.; Tokumaru, Y.; 8 Department of Breast Surgery and Oncology, Tokyo Medical University, Tokyo 160-8402, Japan Mukhopadhyay, S.; Yan, L.; * Correspondence: [email protected]; Tel.: +1-716-8-455-540; Fax: +1-716-8-451-668 Matsuyama, R.; Endo, I.; Takabe, K. Annexin A1 Expression Is Associated Abstract: Annexin A1 (ANXA1) is a calcium-dependent phospholipid-binding protein overexpressed with Epithelial–Mesenchymal in pancreatic cancer (PC).
    [Show full text]
  • S100 Calcium-Binding Protein S100 Proteins
    S S100 Calcium-Binding Protein experiments showed the S100 protein fraction consti- tuted two different dimeric species comprised of two ▶ S100 Proteins b protomers (S100B) or an a, b heterodimer (Isobe et al. 1977). Early members of the S100 protein family were frequently given suffixes based on their localiza- tion or molecular size and included S100P (placental), S100 Proteins S100C (cardiac or calgizzarin), p11 (11 kDa), and MRP8/MRP14 (myeloid regulatory proteins, 8 and Brian R. Dempsey, Anne C. Rintala-Dempsey and 14 kDa). In 1993, initial genetic studies showed that Gary S. Shaw six of the S100 genes were clustered on chromosome Department of Biochemistry, The University of 1q21 (Engelkamp et al. 1993), a number that has Western Ontario, London, ON, Canada expanded since. Based on this observation most of the proteins were renamed according to the physical order they occupy on the chromosome. These include Synonyms S100A1 (formerly S100a), S100A2 (formerly S100L), S100A10 (p11), S100A8/S100A14 (MRP8/MRP14). S100 calcium-binding protein A few S100 proteins are found on other chromosomes including S100B (21q21). Currently there are 27 known S100 family members: S100A1-A18, S100B, S100 Protein Family Members S100G, S100P, S100Z, trichohylin, filaggrin, filaggrin- 2, cornulin, and repetin (Table 1). S100A1, S100A2, S100A3, S100A4, S100A5, S100A6, S100A7, S100A8, S100A9, S100A10, S100A11, S100A12, S100A13, S100A14, S100A15, S100A16, Role of S100 Proteins in Calcium Signaling S100B, S100P, S100G, S100Z, trichohylin, filaggrin, filaggrin-2,
    [Show full text]
  • Calreticulin—Multifunctional Chaperone in Immunogenic Cell Death: Potential Significance As a Prognostic Biomarker in Ovarian
    cells Review Calreticulin—Multifunctional Chaperone in Immunogenic Cell Death: Potential Significance as a Prognostic Biomarker in Ovarian Cancer Patients Michal Kielbik *, Izabela Szulc-Kielbik and Magdalena Klink Institute of Medical Biology, Polish Academy of Sciences, 106 Lodowa Str., 93-232 Lodz, Poland; [email protected] (I.S.-K.); [email protected] (M.K.) * Correspondence: [email protected]; Tel.: +48-42-27-23-636 Abstract: Immunogenic cell death (ICD) is a type of death, which has the hallmarks of necroptosis and apoptosis, and is best characterized in malignant diseases. Chemotherapeutics, radiotherapy and photodynamic therapy induce intracellular stress response pathways in tumor cells, leading to a secretion of various factors belonging to a family of damage-associated molecular patterns molecules, capable of inducing the adaptive immune response. One of them is calreticulin (CRT), an endoplasmic reticulum-associated chaperone. Its presence on the surface of dying tumor cells serves as an “eat me” signal for antigen presenting cells (APC). Engulfment of tumor cells by APCs results in the presentation of tumor’s antigens to cytotoxic T-cells and production of cytokines/chemokines, which activate immune cells responsible for tumor cells killing. Thus, the development of ICD and the expression of CRT can help standard therapy to eradicate tumor cells. Here, we review the physiological functions of CRT and its involvement in the ICD appearance in malignant dis- ease. Moreover, we also focus on the ability of various anti-cancer drugs to induce expression of surface CRT on ovarian cancer cells. The second aim of this work is to discuss and summarize the prognostic/predictive value of CRT in ovarian cancer patients.
    [Show full text]
  • Intracellular Ca2&Plus
    Cell Death and Differentiation (2009) 16, 1126–1134 & 2009 Macmillan Publishers Limited All rights reserved 1350-9047/09 $32.00 www.nature.com/cdd Intracellular Ca2 þ operates a switch between repair and lysis of streptolysin O-perforated cells EB Babiychuk*,1, K Monastyrskaya1, S Potez1 and A Draeger1 Pore-forming (poly)peptides originating from invading pathogens cause plasma membrane damage in target cells, with consequences as diverse as proliferation or cell death. However, the factors that define the outcome remain unknown. We show 2 þ 2 þ that in cells maintaining an intracellular Ca concentration [Ca ]i below a critical threshold of 10 lM, repair mechanisms seal 2 þ 2 þ off ‘hot spots’ of Ca entry and shed them in the form of microparticles, leading to [Ca ]i reduction and cell recovery. Cells 2 þ that are capable of preventing an elevation of [Ca ]i above the critical concentration, yet are unable to complete plasma 2 þ membrane repair, enter a prolonged phase of [Ca ]i oscillations, accompanied by a continuous shedding of microparticles. 2 þ When [Ca ]i exceeds the critical concentration, an irreversible formation of ceramide platforms within the plasma membrane 2 þ and their internalisation drives the dying cells beyond the ‘point of no return’. These findings show that the extent of [Ca ]i elevation determines the fate of targeted cells and establishes how different Ca2 þ -dependent mechanisms facilitate either cell survival or death. Cell Death and Differentiation (2009) 16, 1126–1134; doi:10.1038/cdd.2009.30; published online 27 March 2009 Plasma membrane pores formed by cytotoxic proteins modulators, which, in turn, amplify an ongoing inflammatory and peptides disrupt the permeability barrier in a target response.3,11 The authors further hypothesised that a more 2 þ cell.
    [Show full text]
  • Annexin A1 Is a New Functional Linker Between Actin Filaments and Phagosomes During Phagocytosis
    578 Research Article Annexin A1 is a new functional linker between actin filaments and phagosomes during phagocytosis Devang M. Patel1, Syed Furquan Ahmad1, Dieter G. Weiss1, Volker Gerke2 and Sergei A. Kuznetsov1,* 1Institute of Biological Sciences, Cell Biology and Biosystems Technology, University of Rostock, Albert-Einstein Straße 3, Rostock 18059, Germany 2Institute of Medical Biochemistry, Centre for Molecular Biology of Inflammation, University of Münster, Von-Esmarch-Straße 56, Münster 48149, Germany *Author for correspondence ([email protected]) Accepted 19 October 2010 Journal of Cell Science 124, 578-588 © 2011. Published by The Company of Biologists Ltd doi:10.1242/jcs.076208 Summary Remodelling of the actin cytoskeleton plays a key role in particle internalisation and the phagosome maturation processes. Actin- binding proteins (ABPs) are the main players in actin remodelling but the precise role of these proteins in phagocytosis needs to be clarified. Annexins, a group of ABPs, are known to be present on phagosomes. Here, we identified annexin A1 as a factor that binds to isolated latex bead phagosomes (LBPs) in the presence of Ca2+ and facilitates the F-actin–LBP interaction in vitro. In macrophages the association of endogenous annexin A1 with LBP membranes was strongly correlated with the spatial and temporal accumulation of F-actin at the LBP. Annexin A1 was found on phagocytic cups and around early phagosomes, where the F-actin was prominently concentrated. After uptake was completed, annexin A1, along with F-actin, dissociated from the nascent LBP surface. At later stages of phagocytosis annexin A1 transiently concentrated only around those LBPs that showed transient F-actin accumulation (‘actin flashing’).
    [Show full text]
  • Comprehensive Proteome Profiling of Glioblastoma-Derived Extracellular Vesicles Identifies Markers for More Aggressive Diseas
    J Neurooncol DOI 10.1007/s11060-016-2298-3 LABORATORY INVESTIGATION Comprehensive proteome profiling of glioblastoma-derived extracellular vesicles identifies markers for more aggressive disease Duthika M. Mallawaaratchy1 · Susannah Hallal2,3 · Ben Russell2,3 · Linda Ly3 · Saeideh Ebrahimkhani2,3 · Heng Wei3,4 · Richard I. Christopherson1 · Michael E. Buckland2,3,4 · Kimberley L. Kaufman1,3,4 Received: 14 February 2016 / Accepted: 9 October 2016 © The Author(s) 2016. This article is published with open access at Springerlink.com Abstract Extracellular vesicles (EVs) play key roles in membrane protrusions with proteolytic activity, are asso- glioblastoma (GBM) biology and represent novel sources of ciated with more aggressive disease and are sites of EV biomarkers that are detectable in the peripheral circulation. release. Gene levels corresponding to invasion-related EV Despite this notionally non-invasive approach to assess proteins showed that five genes (annexin A1, actin-related GBM tumours in situ, a comprehensive GBM EV protein protein 3, integrin-β1, insulin-like growth factor 2 recep- signature has not been described. Here, EVs secreted by tor and programmed cell death 6-interacting protein) were six GBM cell lines were isolated and analysed by quan- significantly higher in GBM tumours compared to normal titative high-resolution mass spectrometry. Overall, 844 brain in silico, with common functions relating to actin poly- proteins were identified in the GBM EV proteome, of merisation and endosomal sorting. We also show that Cavi- which 145 proteins were common to EVs secreted by all tron Ultrasonic Surgical Aspirator (CUSA) washings are a cell lines examined; included in the curated EV compen- novel source of brain tumour-derived EVs, demonstrated dium (Vesiclepedia_559; http://microvesicles.org).
    [Show full text]
  • Rage (Receptor for Advanced Glycation End Products) in Melanoma
    RAGE (RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS) IN MELANOMA PROGRESSION A Dissertation Submitted to the Graduate Faculty of the North Dakota State University of Agriculture and Applied Science By Varsha Meghnani In Partial Fulfillment for the Degree of DOCTOR OF PHILOSOPHY Major Department: Pharmaceutical Sciences May 2014 Fargo, North Dakota North Dakota State University Graduate School Title RAGE (RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS) IN MELANOMA PROGRESSION By VARSHA MEGHNANI The Supervisory Committee certifies that this disquisition complies with North Dakota State University’s regulations and meets the accepted standards for the degree of DOCTOR OF PHILOSOPHY SUPERVISORY COMMITTEE: ESTELLE LECLERC Chair BIN GUO STEPHEN O’ROURKE JANE SCHUH Approved: 5/22/2014 JAGDISH SINGH Date Department Chair ABSTRACT The Receptor for Advanced Glycation End Products (RAGE) and its ligands are expressed in multiple cancer types and are implicated in cancer progression. Our lab has previously reported higher transcript levels of RAGE and S100B in advanced staged melanoma patients. The contribution of RAGE in the pathophysiology of melanoma has not been well studied. Based on previous reports, we hypothesized that RAGE, when over-expressed in melanoma cells, promotes melanoma progression. To study the pathogenic role of RAGE in melanoma, a primary melanoma cell line, WM115, was selected and stably transfected with full length RAGE (FL_RAGE) to generate a model cell line over-expressing RAGE (WM115_RAGE). WM266, a sister cell line of WM115, originated from a metastatic tumor of the same patient was used as a metastatic control cell line in the study. After assessing the expression levels of RAGE in the transfected cells, the influence of RAGE on their cellular properties was examined.
    [Show full text]
  • Cellular and Molecular Signatures in the Disease Tissue of Early
    Cellular and Molecular Signatures in the Disease Tissue of Early Rheumatoid Arthritis Stratify Clinical Response to csDMARD-Therapy and Predict Radiographic Progression Frances Humby1,* Myles Lewis1,* Nandhini Ramamoorthi2, Jason Hackney3, Michael Barnes1, Michele Bombardieri1, Francesca Setiadi2, Stephen Kelly1, Fabiola Bene1, Maria di Cicco1, Sudeh Riahi1, Vidalba Rocher-Ros1, Nora Ng1, Ilias Lazorou1, Rebecca E. Hands1, Desiree van der Heijde4, Robert Landewé5, Annette van der Helm-van Mil4, Alberto Cauli6, Iain B. McInnes7, Christopher D. Buckley8, Ernest Choy9, Peter Taylor10, Michael J. Townsend2 & Costantino Pitzalis1 1Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK. Departments of 2Biomarker Discovery OMNI, 3Bioinformatics and Computational Biology, Genentech Research and Early Development, South San Francisco, California 94080 USA 4Department of Rheumatology, Leiden University Medical Center, The Netherlands 5Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology & Immunology Center, Amsterdam, The Netherlands 6Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari, Cagliari, Italy 7Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 8TA, UK 8Rheumatology Research Group, Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham B15 2WB, UK 9Institute of
    [Show full text]
  • Annexin A1 Released in Extracellular Vesicles by Pancreatic Cancer Cells Activates Components of the Tumor Microenvironment
    cells Article Annexin A1 Released in Extracellular Vesicles by Pancreatic Cancer Cells Activates Components of the Tumor Microenvironment, through Interaction with the Formyl-Peptide Receptors Nunzia Novizio 1, Raffaella Belvedere 1 , Emanuela Pessolano 1,2 , Alessandra Tosco 1 , Amalia Porta 1 , Mauro Perretti 2, Pietro Campiglia 1 , Amelia Filippelli 3 and Antonello Petrella 1,* 1 Department of Pharmacy, University of Salerno, Via Giovanni Paolo II 132, 84084 Fisciano, Italy; [email protected] (N.N.); [email protected] (R.B.); [email protected] (E.P.); [email protected] (A.T.); [email protected] (A.P.); [email protected] (P.C.) 2 The William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK; [email protected] 3 Department of Medicine, Surgery and Dentistry, University of Salerno, Via S. Allende 43, 84081 Baronissi, Italy; afi[email protected] * Correspondence: [email protected]; Tel.: +39-089-969-762; Fax: +39-089-969-602 Received: 17 November 2020; Accepted: 17 December 2020; Published: 18 December 2020 Abstract: Pancreatic cancer (PC) is one of the most aggressive cancers in the world. Several extracellular factors are involved in its development and metastasis to distant organs. In PC, the protein Annexin A1 (ANXA1) appears to be overexpressed and may be identified as an oncogenic factor, also because it is a component in tumor-deriving extracellular vesicles (EVs). Indeed, these microvesicles are known to nourish the tumor microenvironment. Once we evaluated the autocrine role of ANXA1-containing EVs on PC MIA PaCa-2 cells and their pro-angiogenic action, we investigated the ANXA1 paracrine effect on stromal cells like fibroblasts and endothelial ones.
    [Show full text]
  • Prognostic Values of S100 Family Members in Ovarian Cancer Patients Yang Bai1,2,3†, Liang-Dong Li4,5†, Jun Li1,2,3 and Xin Lu1,2,3,6*
    Bai et al. BMC Cancer (2018) 18:1256 https://doi.org/10.1186/s12885-018-5170-3 RESEARCH ARTICLE Open Access Prognostic values of S100 family members in ovarian cancer patients Yang Bai1,2,3†, Liang-Dong Li4,5†, Jun Li1,2,3 and Xin Lu1,2,3,6* Abstract Objective: Exhibiting high consistence in sequence and structure, S100 family members are interchangeable in function and they show a wide spectrum of biological processes, including proliferation, apoptosis, migration, inflammation and differentiation and the like. While the prognostic value of each individual S100 in ovarian cancer is still elusive. In current study, we investigated the prognostic value of S100 family members in the ovarian cancer. Methods: We used the Kaplan Meier plotter (KM plotter) database, in which updated gene expression data and survival information are from 1657 ovarian cancer patients, to assess the relevance of individual S100 family mRNA expression to overall survival in various ovarian cancer subtypes and different clinicopathological features. Results: It was found that high expression of S100A2 (HR = 1.18, 95%CI: 1.04–1.34, P = 0.012), S100A7A (HR = 1.3, 95%CI: 1. 04–1.63, P = 0.02),S100A10 (HR = 1.2, 95%CI: 1.05–1.38, P = 0.0087),and S100A16 (HR = 1.23, 95%CI: 1–1.51, P = 0.052) were significantly correlated with worse OS in all ovarian cancer patients, while the expression of S100A1 (HR = 0.87, 95%CI: 0. 77–0.99, P = 0.039), S100A3 (HR = 0.83, 95%CI: 0.71–0.96, P = 0.0011), S100A5 (HR = 0.84, 95%CI: 0.73–0.97, P = 0.017), S100A6 (HR = 0.84, 95%CI: 0.72–0.98, P = 0.024), S100A13 (HR = 0.85, 95%CI:0.75–0.97, P = 0.014) and S100G (HR = 0.86, 95%CI: 0.74–0.99, P = 0.041) were associated with better prognosis.
    [Show full text]